Abstract:The tumor microenvironment is a complex space comprised of normal, cancer and immune cells. The macrophages are considered as the most abundant immune cells in tumor microenvironment and their function in tumorigenesis is interesting. Macrophages can be present as M1 and M2 polarization that show anti-cancer and oncogenic activities, respectively. Tumor-associated macrophages (TAMs) mainly have M2 polarization and they increase tumorigenesis due to secretion of factors, cytokines and affecting molecular pathways. Hepatocellular carcinoma (HCC) is among predominant tumors of liver that in spite of understanding its pathogenesis, the role of tumor microenvironment in its progression still requires more attention. The presence of TAMs in HCC causes an increase in growth and invasion of HCC cells and one of the reasons is induction of glycolysis that such metabolic reprogramming makes HCC distinct from normal cells and promotes its malignancy. Since M2 polarization of TAMs stimulates tumorigenesis in HCC, molecular networks regulating M2 to M1 conversion have been highlighted and moreover, drugs and compounds with the ability of targeting TAMs and suppressing their M2 phenotypes or at least their tumorigenesis activity have been utilized. TAMs increase aggressive behavior and biological functions of HCC cells that can result in development of therapy resistance. Macrophages can provide cell–cell communication in HCC by secreting exosomes having various types of biomolecules that transfer among cells and change their activity. Finally, non-coding RNA transcripts can mainly affect polarization of TAMs in HCC.

Research advances in tumor-associated macrophages in hepatocellular carcinoma microenvironment

Research Progress on Cancer-Associated Fibroblasts in Hepatocellular Carcinoma

Macrophages as targets in hepatocellular carcinoma therapy

Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma

Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy

Tumor-Associated Macrophages in Tumor Immunity (vol <i>11</i>, <i>583084</i>, <i>2020</i>)

The role of tumor‐associated macrophages in hepatocellular carcinoma progression: A narrative review

Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?

Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Tumor‑associated macrophages activated in the tumor environment of hepatocellular carcinoma: Characterization and treatment (Review)

Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress

Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma

Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review)

Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression

Decoding the spatiotemporal heterogeneity of tumor-associated macrophages

Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)

Targeting tumor-associated macrophages for cancer treatment

Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer

Tumor-associated macrophages: from basic research to clinical application

Tumor-associated Macrophages in Lung Carcinoma: from Mechanism to Therapy.